A 31-Week, Efficacy, Safety and Tolerability Study of Eszopiclone 3 mg Co-Administered With Venlafaxine in Subjects With Major Depressive Disorder (MDD) and Co-Existing Insomnia.
Phase of Trial: Phase III
Latest Information Update: 04 Jul 2012
At a glance
- Drugs Eszopiclone; Venlafaxine
- Indications Insomnia; Major depressive disorder
- Focus Therapeutic Use
- Acronyms AVERT
- Sponsors Sunovion Pharmaceuticals
- 04 Jul 2012 Planned number of patients changed from 640 to 700 as reported by European Clinical Trials Database record
- 04 Jul 2012 Pfizer added as associations as reported in the European Clinical Trials Database record
- 13 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.